NMRA

Neumora Therapeutics, Inc.

BS score 14.8LOWPHASE3 · mkt cap $378.6M · rev ttm $0

drug hypothesis

NMRA-335140 modulates Not specified in provided filing to treat Major Depressive Disorder.

moa:Not specified in provided filing

score breakdown

trial design0

base rate disconnect7

language red flags60

composite14.8

valuation analysis

market cap$378.6M

revenue ttm$0

phasePHASE3

historical base rate30%

disconnect ratio0.3x

meta

cik0001885522

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 3, randomized, quadruple-blind, placebo-controlled trial enrolling 332 participants with Major Depressive Disorder

primary endpoint:Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score

claimed differentiation

Not specified in provided filing

language red flags

Insufficient filing text provided for analysis - only trial identifier and basic trial parameters available
No business section content from SEC filing included in request
Cannot assess claims of differentiation, mechanism details, or risk disclosures without full filing text

company-stated risks

upcoming catalysts